6 Dimensions Capital Closed Oversubscribed 1st USD Fund and RMB Fund, Bringing Total AUM...

We are pleased that 6 Dimensions Capital has announced the final close of its inaugural US dollar fund and RMB fund at US $533 million and RMB2.06 billion respectively, both exceeded the original...

WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major therapeutic areas. RPG will become a wholly-owned...

WuXi AppTec Receives 2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership...

We are honored to announce WuXi AppTec has been awarded the 2017 Frost & Sullivan Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award. The award is part of the...

WuXi NextCODE Completes $240 Million Series B Financing

We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series B round with investment from a consortium...

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics CGMP Manufacturing Facilities for...

We are pleased to announce that the U.S. Food and Drug Administration has completed the Pre-License Inspection (PLI) of WuXi Biologics cGMP manufacturing facilities for production of TMB-355 (ibalizumab) with no...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

A Futuristic Biopharma Company Addressing Some of the World’s Biggest Health...

By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) For the past few years, PureTech Health has been building a new R&D model for advancing breakthrough...